Retatrutide: What the Current Research Shows

By Vitality Peps Research Team, updated August 2026.

Retatrutide (LY3437943) is an investigational triple receptor agonist that has drawn substantial attention in metabolic research literature. This overview summarises what published work describes, how the compound is handled in a laboratory setting, and where the evidence currently stops.

What retatrutide is

Retatrutide is a synthetic peptide described in the literature as a single molecule with agonist activity at three receptors: GIP, GLP-1 and glucagon. That triple profile is why it is often referred to informally as a GLP-3 or triple G compound. It is structurally distinct from dual agonists such as tirzepatide, which act at GIP and GLP-1 only.

The compound is investigational. It has not completed the regulatory approval process in the European Union or elsewhere, and no marketing authorisation exists for it. Everything below describes published research, not an approved use.

Why the triple mechanism is studied

Published phase 2 work reported in the New England Journal of Medicine characterises the pharmacodynamic profile of the molecule across the three receptor targets. The research interest lies in whether simultaneous activity at glucagon alongside the two incretin receptors produces a different metabolic signature than incretin activity alone.

Because the compound is still under investigation, the literature is best read as characterising a mechanism rather than establishing an outcome. Reviews published since 2023 consistently note that long term data is not yet available.

Handling in a research setting

Retatrutide is supplied lyophilised. Standard laboratory handling for a lyophilised peptide applies:

Common questions in the literature

Storage duration after reconstitution: the general laboratory convention for bacteriostatic water preparations is refrigerated storage measured in weeks rather than months, with the exact window depending on the peptide and the diluent used.

Comparison with dual agonists: the distinguishing variable in the published work is glucagon receptor activity. Any comparison beyond receptor binding is not currently supported by head to head data.

Concentration: this is a calculation, not a recommendation. Our reconstitution calculator converts vial mass and diluent volume into a concentration and a syringe mark for research measurement.

Regulatory and research use status

Retatrutide sold by Vitality Peps is supplied strictly for in vitro laboratory research. It is not a medicine, not a supplement, and not for human or veterinary consumption. Nothing in this article should be read as guidance for use in humans.

Sources

Related guides

For research purposes only. Not for human consumption.